By elucidating the role of the CEBPB–DUSP1 regulatory axis, we pave the way for novel therapeutic interventions aimed at rebalancing dysregulated MAPK signaling and mitigating CRC progression. This evidence concerns the gene CEBPB and colorectal carcinoma.